159 related articles for article (PubMed ID: 7734294)
1. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer.
Duffy MJ; Blaser J; Duggan C; McDermott E; O'Higgins N; Fennelly JJ; Tschesche H
Br J Cancer; 1995 May; 71(5):1025-8. PubMed ID: 7734294
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
4. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
[TBL] [Abstract][Full Text] [Related]
5. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas.
Iwata H; Kobayashi S; Iwase H; Masaoka A; Fujimoto N; Okada Y
Jpn J Cancer Res; 1996 Jun; 87(6):602-11. PubMed ID: 8766524
[TBL] [Abstract][Full Text] [Related]
6. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.
Fernandez-Garcia B; Eiró N; Marín L; González-Reyes S; González LO; Lamelas ML; Vizoso FJ
Histopathology; 2014 Mar; 64(4):512-22. PubMed ID: 24117661
[TBL] [Abstract][Full Text] [Related]
8. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
Jones JL; Glynn P; Walker RA
J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
[TBL] [Abstract][Full Text] [Related]
9. High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
Remacle A; McCarthy K; Noël A; Maguire T; McDermott E; O'Higgins N; Foidart JM; Duffy MJ
Int J Cancer; 2000 Mar; 89(2):118-21. PubMed ID: 10756061
[TBL] [Abstract][Full Text] [Related]
10. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
Remacle AG; Noël A; Duggan C; McDermott E; O'Higgins N; Foidart JM; Duffy MJ
Br J Cancer; 1998 Mar; 77(6):926-31. PubMed ID: 9528836
[TBL] [Abstract][Full Text] [Related]
11. Secretion of gelatinases and tissue inhibitors of metalloproteinases by human lung cancer cell lines and revertant cell lines: not an invariant correlation with metastasis.
Zucker S; Lysik RM; Malik M; Bauer BA; Caamano J; Klein-Szanto AJ
Int J Cancer; 1992 Sep; 52(3):366-71. PubMed ID: 1399111
[TBL] [Abstract][Full Text] [Related]
12. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases.
Binder C; Hagemann T; Husen B; Schulz M; Einspanier A
Mol Hum Reprod; 2002 Sep; 8(9):789-96. PubMed ID: 12200455
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients.
Heo DS; Choi H; Yeom MY; Song BJ; Oh SJ
Oncol Rep; 2014 Apr; 31(4):1567-72. PubMed ID: 24481627
[TBL] [Abstract][Full Text] [Related]
14. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
Peterson JT; Li H; Dillon L; Bryant JW
Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-17F affects cartilage matrix turnover by increasing the expression of collagenases and stromelysin-1 and by decreasing the expression of their inhibitors and extracellular matrix components in chondrocytes.
Tanigawa S; Aida Y; Kawato T; Honda K; Nakayama G; Motohashi M; Suzuki N; Ochiai K; Matsumura H; Maeno M
Cytokine; 2011 Nov; 56(2):376-86. PubMed ID: 21885294
[TBL] [Abstract][Full Text] [Related]
17. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines.
Mackay AR; Ballin M; Pelina MD; Farina AR; Nason AM; Hartzler JL; Thorgeirsson UP
Invasion Metastasis; 1992; 12(3-4):168-84. PubMed ID: 1284126
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
19. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer.
Singh RD; Nilayangode H; Patel JB; Shah FD; Shukla SN; Shah PM; Patel PS
Int J Biol Markers; 2011; 26(1):27-36. PubMed ID: 21337314
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]